Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01433016
Other study ID # HCC-BID-0411
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date November 2011
Est. completion date May 2013

Study information

Verified date December 2022
Source Meridian Bioscience, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Exalenz clinical investigation is a multicenter, non-randomized, study of the ¹³C-Octanoate Breath Test (OBT). The present study is a feasibility trial, which aims to evaluate the capability of the OBT measurement to differentiate between presence and absence of HCC determined by Magnetic Resonance Imaging (MRI) in patients with chronic liver disease.


Description:

The Octanoate Breath Test (OBT) developed by Exalenz is performed by the BreathID System consists of the BreathID device and a test kit containing a nasal cannula, a calibration gas container and a non-radioactive isotope ¹³C- Octanoate solution, and measures and computes the ratio between ¹³CO2 and 12CO2 in the patient's exhaled breath. This study's aim is to provide data on this novel system to dynamically and accurately assess liver function at the bed side. It is hoped that the system will provide prognostic information faster than is achieved at present with traditional methods. It is hypothesized that in the future the OBT may have an impact on decision making and clinical practice in this group of HCC patients, allowing a greater chance for proper management and hence survival.


Recruitment information / eligibility

Status Terminated
Enrollment 20
Est. completion date May 2013
Est. primary completion date May 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Any patients with chronic liver disease at risk for HCC. - Age > 18 years. - Patient has an MRI result (positive or negative for HCC) up to 3 months prior to recruitment or will be scheduled for an MRI during the trial period. - Patient is naïve to any HCC treatment. Exclusion Criteria: - Underwent any RFA or TACE or Oral HCC treatments. - Portal vein thrombosis. - Prior TIPS placement. - Severe congestive heart failure (LVEF on echocardiogram < 20%). - Severe pulmonary hypertension (By echocardiogram, PAS >45 mmHg). - Uncontrolled diabetes mellitus (HBA1C >9.5%). - Any autoimmune disorder, which is currently being treated with prednisone or any other immune suppressive medication. - Previous surgical bypass surgery for morbid obesity (BMI >45). - Extensive small bowel resection. - Patients currently receiving total parenteral nutrition if they have contraindications to oral drugs. - Women who are pregnant or breast feeding. - Patients with an acute current exacerbation of chronic obstructive pulmonary disease or bronchial asthma. - Patient has taken drugs that can interfere with octanoate metabolism or can also cause NAFLD independent of the metabolic syndrome, including: corticosteroids, amiodarone, tetracycline, valproic acid, methotrexate, stavudine, zidovudine. - Patient, based on the opinion of the investigator, should not be enrolled into this study. - Patient is unable or unwilling to sign informed consent. - Patients that are participating in other clinical trials evaluating experimental treatments or procedures

Study Design


Intervention

Drug:
13C Sodium Octanoate
13C labeled Sodium Octanoate Substrate is provided in powder form in doses of 100mg for single breath test, and is dissolved in 150cc of tap water before ingestion. Duration of the observation after the drug ingestion is one hour.

Locations

Country Name City State
Canada Toronto General Hospital Toronto Ontario

Sponsors (6)

Lead Sponsor Collaborator
Meridian Bioscience, Inc. Hadassah Medical Organization, Henry Ford Health System, Medical University of South Carolina, Northwestern University, Toronto General Hospital

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary PDR Peak PDR peak - the rate at which the 13C labeled substrate is metabolized, percentage dose recovery. At study day one after one hour
See also
  Status Clinical Trial Phase
Completed NCT03704792 - Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference N/A
Terminated NCT02949375 - Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease Phase 2
Active, not recruiting NCT01205074 - ¹³C-Methacetin Breath Test (MBT) Methodology Study Phase 2/Phase 3
Completed NCT00756171 - Colesevelam Versus Placebo in Cholestatic Pruritus Phase 2/Phase 3
Completed NCT01195181 - Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. Phase 4
Completed NCT05044663 - Liver and Splenic Stiffness in Predicting Esophageal Varices Needing Treatment in NASH Related Compensated Advanced Chronic Liver Disease.
Recruiting NCT04588077 - Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis Phase 4
Recruiting NCT04802954 - Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients N/A
Recruiting NCT04622449 - Etiopathogenesis of Anemia in Chronic Liver Disease
Enrolling by invitation NCT05836246 - The Development of Quantitative Ultrasound Imaging Software Platform
Completed NCT03087344 - Postprandial Liver and Spleen Stiffness Measurements in the Noninvasive Diagnosis of Cirrhosis N/A
Completed NCT04751045 - Comparison and Outcomes of Endoscopic Ultrasound Liver Biopsies Versus Percutaneous Liver Biopsies N/A
Not yet recruiting NCT04526548 - A Diagnostic Study on Patients With Drug-induced Liver Injury
Withdrawn NCT02899325 - FDGal PET/CT to Detect Hepatocellular Carcinoma
Suspended NCT02650011 - Clinical Features and Natural History of Acute-on-Chronic Liver Failure in Korean Patients With Chronic Liver Disease
Terminated NCT02530567 - Non-invasive Evaluation of Portal Pressure by MRI N/A
Completed NCT01851252 - MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy Phase 1
Terminated NCT01756690 - Predicting Lung Injury From Transfusion in Patients With Liver Disease N/A
Completed NCT01600105 - Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI) Phase 4
Completed NCT01008293 - Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life Phase 2/Phase 3